Table 4.

Biological data, relapse localisation, treatment and survival time in all patients still alive when database was frozen

ID	β-Catenin status	MYC / MYCN ampl	Ch17	CCR1 (mo)	Relapse site	Surgery	RT	Chemotherapy	IT	HDSCR	OS (mo)
1	Neg	No	No	30	PF local	GTR	No	CBDCA, VP-16	MTX	No	114
2	Neg	No	No	27	PF local	GTRa	No	TMZ	No	No	95
3b	ICH + Mut+	No	No	42	ST local	No	No	TMZ, VP-16, gemcitabine, oxaliplatinc	No	No	87
4	No data	No data	No data	65	Spine multiple	PR	No	CBDCA, CPM	No	No	107
5	Neg	No data	No data	44	Spine multiple	No	Yes	CBDCA, CPM, VP-16	No	Yes	78
6	Neg	No	No	51	ST local	Yes	Yes	TMZ	No	No	82
7	Neg	No data	No data	75	PF + spine	Yes	No	No	No data	No	98
8	Neg	No	No	95	PF local	GTR	No	Yes	No	Yes	113
9	Neg	No	No	72	PF	Yes	No	Yes	No data	Yes	78

Histology: classic MB (9/9). One patient was randomised to HFRT at primary treatment (ID 8), the rest to STRT

CBDCA carboplatin, Ch17 chromosome 17 imbalances/diploid background, CCR1 time in continuous complete remission after primary diagnosis (months), CPM cyclophosphamide, GTR gross total resection, HDSCR high dose chemotherapy with autologous stem cell rescue, HFRT hyperfractionated radiotherapy, ICH+ immunohistochemistry for nuclear β-catenin positive, IT intrathecal chemotherapy, mo months, Mut+ CTNNB1 mutation positive, OS overall survival after primary diagnosis (months), PF posterior fossa, PR partial resection, RT radiotherapy, ST supratentorial, STRT standard (conventional) radiotherapy, TMZ temozolomide, VP-16 etoposide

^aSurgery performed at 3rd local relapse

^bSame as case W2 in Table 2

^cChemotherapy initiated after observation period, when relapsed tumour progressed